Ranbaxy Ducks Wider Recall In Glass Particles Class Action

Law360, New York (March 6, 2013, 4:54 PM EST) -- A New Jersey federal judge Tuesday rejected a proposed class action’s demand for a wider recall of Ranbaxy Laboratories Ltd.'s generic version of Lipitor, a setback for patients who claim pills tainted with glass pose a serious health risk.

U.S. District Judge Peter G. Sheridan refused to grant a preliminary injunction that would extend the recall of atorvastatin from the retail level to the consumer level, a move plaintiffs have described as “common sense” despite assurances from the U.S. Food and Drug Administration that grain-of-sand-sized bits...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

FENWICK v. RANBAXY PHARMACEUTICALS, INC. et al


Case Number

3:12-cv-07354

Court

New Jersey

Nature of Suit

Other Statutory Actions

Judge

Peter G. Sheridan

Date Filed

November 29, 2012

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.